

Martin Kleinschmidt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3800304/publications.pdf>

Version: 2024-02-01

9
papers

465
citations

1162889
8
h-index

1474057
9
g-index

9
all docs

9
docs citations

9
times ranked

691
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure and Dynamics of Meprin \hat{I}^2 in Complex with a Hydroxamate-Based Inhibitor. International Journal of Molecular Sciences, 2021, 22, 5651.	1.8	7
2	Targeting isoaspartate-modified $A\hat{I}^2$ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology. Alzheimer's Research and Therapy, 2020, 12, 149.	3.0	10
3	Development of the clinical candidate PBD-C06, a humanized pGlu3- $A\hat{I}^2$ -specific antibody against Alzheimer's disease with reduced complement activation. Scientific Reports, 2020, 10, 3294.	1.6	17
4	Effector function of anti-pyroglutamate-3 $A\hat{I}^2$ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. Alzheimer's Research and Therapy, 2020, 12, 12.	3.0	26
5	Structural and functional analyses of pyroglutamate-amyloid- \hat{I}^2 -specific antibodies as a basis for Alzheimer immunotherapy. Journal of Biological Chemistry, 2017, 292, 12713-12724.	1.6	24
6	An anti-pyroglutamate-3 $A\hat{I}^2$ vaccine reduces plaques and improves cognition in APPswe/PS1 $\hat{E}9$ mice. Neurobiology of Aging, 2015, 36, 3187-3199.	1.5	45
7	Pyroglutamate-3 Amyloid- \hat{I}^2 Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease-Like Transgenic Mouse Models. American Journal of Pathology, 2013, 183, 369-381.	1.9	102
8	Passive Immunization against Pyroglutamate-3 Amyloid- \hat{I}^2 Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. Neurodegenerative Diseases, 2012, 10, 265-270.	0.8	63
9	Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides. Biochemistry, 2009, 48, 7072-7078.	1.2	171